TrialThe Lancet. Oncology2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
Jean-Yves Blay et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
63 papers cite itlatest 60 shown
this paperpooled ittrialcites it